Skip to main content

Morningside Venture Investments Ltd's Form 4/A amendment

Amended

Amylyx Pharmaceuticals, Inc. (AMLX) · filed Mar 17, 2022

Accession no.
0000899243-22-011432
Filed
Mar 17, 2022, 5:14 PM ET
Trade date
Jan 11, 2022
Filing delay
65 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Jan 25, 2022

This filing lists 2 non-derivative transactions and 4 derivative transactions. Open-market purchases total $5.00M. It was filed 65 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Morningside Venture Investments LtdCIK 000154311210% Owner
Mvil, LLCCIK 000191458310% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 11, 2022Common StockCConversionAcquired+10,415,650–F1–10,415,650IndirectDuplicate filing
Jan 11, 2022Common StockPPurchaseAcquired+263,158$19.00+$5,000,00210,678,808IndirectDuplicate filing

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 11, 2022Common StockCConversionDisposed−1,409,035$0.00$00IndirectDuplicate filing
Jan 11, 2022Common StockCConversionDisposed−6,410,964$0.00$00IndirectDuplicate filing
Jan 11, 2022Common StockCConversionDisposed−974,107$0.00$00IndirectDuplicate filing
Jan 11, 2022Common StockCConversionDisposed−1,621,544$0.00$00IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

Referenced by the price of 1 transaction in Table I.

F2

Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC.

F3

The shares of Series C-2 Preferred Stock and the Common Stock received upon conversion of the C-2 Preferred Stock are held by MVIL LLC.

Remarks

The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.

Read the full filing on SEC EDGAR (opens in a new tab)